About: Epidemiology, Outcome and Risk Factors Analysis of Viral Infections in Children and Adolescents Undergoing Hematopoietic Cell Transplantation: Antiviral Drugs Do Not Prevent Epstein

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Epidemiology, Outcome and Risk Factors Analysis of Viral Infections in Children and Adolescents Undergoing Hematopoietic Cell Transplantation: Antiviral Drugs Do Not Prevent Epstein–Barr Virus Reactivation Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Epidemiology, Outcome and Risk Factors Analysis of Viral Infections in Children and Adolescents Undergoing Hematopoietic Cell Transplantation: Antiviral Drugs Do Not Prevent Epstein–Barr Virus Reactivation
Creator	Bartoszewicz, Natalia Czyzewski, Krzysztof Demidowicz, Ewa Dziedzic, Magdalena Fraczkiewicz, Jowita Galazka, Przemyslaw Gozdzik, Jolanta Salamonowicz, Malgorzata Styczynski, Jan Zajac-Spychala, Olga Zaucha-Prazmo, Agnieszka
Source	Medline; PMC
abstract	OBJECTIVE: The analysis of epidemiology, risk factors and outcome of viral infections in children and adolescents after hematopoietic cell transplantation (HCT). METHODS: In this multicenter nationwide study a total of 971 HCT procedures (741 allo-HCT; 230 auto-HCT) over a period of 6 years were analyzed. RESULTS: During this period 801 episodes of viral infections were diagnosed in 442 patients. The incidence of viral infections was 57.9% in allo-HCT and 4.8% in auto-HCT patients. The most frequent infections after allo-HCT were caused by cytomegalovirus (CMV), polyoma BK virus (BKV) and Epstein–Barr virus (EBV). The majority of infections occurred within the first 4 months after allo-HCT and over 80% required pharmacotherapy or symptomatic therapy. The median time of treatment of specific viral infection ranged from 7 (for EBV) to 24 (for CMV) days. The highest mortality was observed in case of CMV infection. The risk factors for viral infections were allo-HCT, acute leukemia, acute and chronic graft versus host disease (a/cGVHD), and matched unrelated donor (MUD)/mismatched unrelated donor (MMUD)-HCT. The risk factor for death from viral infection were CMV-IgG seropositivity in acute lymphoblastic leukemia recipient, and MUD/MMUD-HCT. The incidence of EBV infection requiring pre-emptive treatment with rituximab in allo-HCT children was 19.3%. In 30.8% cases of EBV infection, these episodes were preceded by other viral infection and treated with antivirals, which did not prevent development of EBV-DNA-emia with need of rituximab treatment in 81.5% cases. In 47.7% of these cases, GVHD was a factor enabling development of significant EBV-DNA-emia during antiviral therapy of other infection. CONCLUSION: We have shown that antiviral drugs do not prevent EBV reactivation in allo-HCT pediatric patients.
has issue date	2019-12-17(xsd:dateTime)
bibo:doi	10.2147/idr.s224291
bibo:pmid	31908501
has license	cc-by-nc
sha1sum (hex)	7d780290822a5408a54dfdf2ae32139cf1a2892c
schema:url	https://doi.org/10.2147/idr.s224291
resource representing a document's title	Epidemiology, Outcome and Risk Factors Analysis of Viral Infections in Children and Adolescents Undergoing Hematopoietic Cell Transplantation: Antiviral Drugs Do Not Prevent Epstein–Barr Virus Reactivation
has PubMed Central identifier	PMC6925545
has PubMed identifier	31908501
schema:publication	Infect Drug Resist
resource representing a document's body	covid:7d780290822a5408a54dfdf2ae32139cf1a2892c#body_text
is schema:about of	named entity 'factor' named entity 'viral infections' named entity 'case' named entity 'epidemiology' named entity 'development' named entity 'infections' named entity 'Hematopoietic' covid:arg/7d780290822a5408a54dfdf2ae32139cf1a2892c named entity 'EBV' named entity 'infections' named entity 'MUD' named entity 'viral infections' named entity 'infection' named entity 'Methods' named entity 'median' named entity 'CMV' named entity 'time' named entity 'infection' named entity 'EBV infection' named entity 'antivirals' named entity 'viral infection' named entity 'Epstein-Barr virus' named entity 'CMV' named entity 'acute lymphoblastic leukemia' named entity 'seropositivity' named entity 'risk factor' named entity 'rituximab' named entity 'acute leukemia' named entity 'Risk Factors' named entity 'Hematopoietic Cell' named entity 'Epidemiology' named entity 'EBV' named entity 'viral infections' named entity 'urine' named entity 'EBV infection' named entity 'MUD' named entity 'viral infections' named entity 'HSCT' named entity 'EBV infection' named entity 'EBV' named entity 'EBV' named entity 'influenza' named entity 'AML' named entity 'ethics committee' named entity 'infection' named entity 'thymidine kinase' named entity 'cidofovir' named entity 'BKV' named entity 'viral infection' named entity 'PTLD' named entity 'hemorrhagic cystitis' named entity 'hematopoietic cell' named entity 'oseltamivir' named entity 'infection' named entity 'cidofovir' named entity 'viral infections' named entity 'probenecid' named entity 'viral infections' named entity 'HSV' named entity 'PTLD' named entity 'Nicolaus Copernicus University' named entity 'rhinovirus' named entity 'EBV' named entity 'viral infection' named entity 'infection' named entity 'viral infection' named entity 'EBV' named entity 'lytic' named entity 'survival rate' named entity 'viral infection' named entity 'cumulative incidence'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software